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The native HIV-1 Env complex consists of a gp120/gp41 trimer, but surface plasmon resonance
(SPR)-directed binding studies for gp120-binding agents were almost exclusively performed on
monomeric gp120. SPR-directed binding kinetics of monomeric gp120 and trimeric gp140 were
investigated for a broad variety of envelope (Env)-binding agents. Similar kinetics for carbohy-
drate-binding agents (CBAs), the antibody 2G12 and sCD4 were observed, irrespective of the oligo-
meric state of gp120 that either contain the native mixture of complex and high-mannose
N-glycans or that contain exclusively oligomannose N-glycans. The generally comparable kinetic
properties of CBA, 2G12 and sCD4 binding to monomeric gp120 and trimeric gp140 indicate that
monomeric gp120 is a good surrogate molecule for native HIV-1 Env trimer to investigate the bind-
ing afﬁnities of Env-binding compounds.
Structured summary of protein interactions:
gp120 binds to GRFT by surface plasmon resonance (View Interaction: 1, 2)
gp120 binds to UDA by surface plasmon resonance (View Interaction: 1, 2)
gp120 binds to AH by surface plasmon resonance (View Interaction: 1, 2)
 2013 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
The presence of gp120/gp41 in the envelope (Env) of HIV-1 is of
crucial importance for viral infectivity and transmission. The Env
gp120/gp41 is very densely glycosylated, with up to 50% of themass of gp120 arising from these carbohydrates. The number of
carbohydrate attachment sites and the level to which they are gly-
cosylated (i.e. high mannose-, hybrid- and complex-type N-gly-
cans) are virus isolate-dependent and varies during the course of
HIV infection [1–3].
A variety of carbohydrate-binding agents (CBAs) such as the
prokaryotic actinohivin (AH) [4], cyanovirin (CV-N) [5], microvirin
(MVN) [6], the red algae-derived grifﬁthsin (GRFT) [7], the plant
lectins Hippeastrum hybrid agglutinin (HHA) [8] and Urtica dioica
(UDA) [9] and the antibiotics pradimicin A (PRM-A) and pradimicin
S (PRM-S) [10,11] are able to block HIV entry into target cells as
well as dendritic cell-speciﬁc intercellular adhesion molecule 3
(ICAM-3) grabbing non-integrin (DC-SIGN)-directed HIV transmis-
sion presumably by their interaction with the glycans on HIV
gp120 [12]. It has indeed been demonstrated that HIV-1 Env glyco-
protein gp120 is the primary target for several CBAs and that they
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with their target cells. These agents also prevent the capture and
subsequent transmission of virus particles by the DC-SIGN receptor
that is present on cells of the innate immune system [13–15].
A typical HIV-1 virion contains 10–14 Env spikes [16]. These na-
tive Env spikes consist of heterodimeric trimers of the precursor
glycoprotein gp160 which are then cleaved by a host furin protease
into 2 subunits designated gp120 and gp41. The mature HIV Env
spikes consist of trimers of the surface glycoprotein gp120 non-
covalently associated with trimers of the fusion transmembrane
glycoprotein gp41 [17]. Cleaved and functional gp120/gp41 trimer
complexes are unstable and difﬁcult to produce as recombinant
products. Therefore gp140, the ectodomain of trimeric gp160, has
been used to mimic the native state of the HIV Env spikes [18]. It
has indeed been demonstrated that soluble gp140 trimers mimic
the quaternary structure of native trimeric Env [19]. However,
the native trimer Env has relevant immunologic differences with
gp120 monomers [[20], and references therein] and displays a un-
ique quaternary structure that can form speciﬁc complexes with
antibodies [21]. Also, the trimeric state of gp120 contains small dif-
ferences in its structure in the presence of the non-covalently
bound gp41 [22]. Thus, for many studies, it might be advisable to
use trimeric rather than monomeric Env gp120.
Despite the fact that the HIV-1 Env appears as a trimeric com-
plex, binding studies of most gp120 binding agents, including
CBAs, were virtually exclusively performed so far with monomeric
gp120 glycoprotein [23–28]. The relevance of binding kinetics with
monomeric gp120 is often questioned. To study in more detail the
impact of the oligomeric state of the Env gp120 on ligand binding,
we performed an extensive afﬁnity study of several CBAs and other
Env-binding agents with monomeric JR-FL gp120 and trimeric JR-
FL gp140, expressed in 293T cells, using surface plasmon resonance
(SPR) technology. Furthermore we present SPR-data emphasizing
the different kinetic proﬁles of CBAs when Env lacks complex gly-
cans and is exclusively occupied by a glycan shield of terminally
mannosylated N-glycans.2. Materials and methods
2.1. Test compounds
Actinohivin (AH), Grifﬁthsin (GRFT), the mannose-speciﬁc plant
lectin from Hippeastrum hybrid (HHA) and Urtica dioica (UDA) and
the antibody Pradimicin S (PRM-S) were obtained as previously de-
scribed [4,7–9,11]. The HIV antibodies 2G12, b12 and 2F5 were
purchased from Polymun Scientiﬁc (Vienna, Austria). The anti-
gp120 V3 loop mAb PA-1 was a gift from Bill Olson (Progenics
Pharmaceutical, Tarrytown, NY). Recombinant sCD4 was obtained
from USBiological (Swampscott, MA). DC-SIGN-Fc was purchased
from R&D Systems (Minneapolis, MN). Antibody (Ab) D7324 was
ordered from Aalto Bio Reagents (Dublin, Ireland).
2.2. Production of gp120 monomers and gp140 trimers
The expression constructs of JR-FL gp120 containing the D7324
epitope in the C5 and JR-FL gp140 SOSIP.R6 with a D7324-epitope
tag at the C-terminus, were described previously [29]. HEK 293T
and 293S GnTI/ cells were cultured and maintained in DMEM
(Invitrogen, Breda, The Netherlands) supplemented with 10% heat
inactivated fetal calf serum (FCS; HyClone, Perbio, Etten-Leur, The
Netherlands), minimal essential medium non-essential amino
acids (0.1 mM; Invitrogen, Breda, The Netherlands) and penicil-
lin/streptomycin (both at 100 U/ml). The cell lines were transiently
transfected with plasmids expressing recombinant Env using the
lipofectamin 2000 reagent according to the manufacturer’s proto-col (Invitrogen, Carlsbad, CA). The cell supernatants were har-
vested 3 days after transfection and stored in aliquots at 80 C.
2.3. SDS–PAGE and Western Blotting
Env proteins were detected using SDS–polyacrylamide gel elec-
trophoresis (SDS–PAGE) and Western blotting using the anti-
gp120 V3 loop mAb PA-1. Env protein from transfected cell culture
supernatant was diluted with an equal volume of SDS sample buf-
fer containing 0.1 M DTT and denatured for 10 min at 95. Samples
were loaded onto a 8% Tris–glycine gel and gel electrophoresis was
performed for 2 h at 125 V at room temperature. Proteins were
semi-dry transferred on a prepared Immobilin-P Transfer mem-
brane (Millipore cat# IPV00010) and Western blotting was per-
formed as previously described [30]. JR-FL Env were labeled with
0.2 lg per ml primary PA-1 mAb, and visualized using a secondary
HRP-labeled goat-anti-mouse IgG (1:5000 dilution) followed by
Western Lightning ECL solution (PerkinElmer, Groningen, The
Netherlands).
2.4. Surface plasmon resonance (SPR) analysis
All interaction studies were performed with a Biacore T200
instrument (GE Healthcare, Uppsala, Sweden) at 25 C in HBS-P
running buffer (10 mM HEPES, 150 mM NaCl and 0.05% surfactant
P20; pH 7.4) supplemented with 10 mM CaCl2. Recombinant HIV-1
Env proteins were supplied as supernatants. To circumvent further
protein puriﬁcation and scaling-up steps, the recombinant Env
proteins were constructed with a D7324 tag and this tag was used
to capture the Env proteins via Ab D7324 on a sensor chip. Ab
D7324 was therefore covalently immobilized on the carboxyme-
thylated dextran matrix of a CM5 chip in 10 mM sodium acetate,
pH 4.0, using standard amine coupling chemistry which includes
as ﬁnal step the deactivation of 1-ethyl-3-(3-dimethylaminopro-
pyl)carbodiimide hydrochloride/N-hydroxysuccinimide (EDC/
NHS) activated groups to which no Ab D7324 has been coupled
with 1 M ethanolamine. This was followed by the capturing of
D7324 tagged Env protein from the supernatants. However, the
off-rate for the interaction between D7324 and Ab D7324 was
too fast to carry out further reliable kinetic analyses with the CBAs.
Therefore the interaction between D7324 and Ab D7324 was cova-
lently linked with an extra ﬁxation step by a short pulse (120 s) of a
mixture of 0.2 M EDC and 0.05 M NHS. Low immobilization levels,
between 180 and 430 response units (RU), of recombinant mono-
meric gp120 and trimeric gp140 were achieved to avoid rebinding
events during the experiment and to obtain reliable binding kinet-
ics. For kinetic analysis of the CBAs and other tested HIV envelope
interacting molecules, sensorgrams were generated by injecting
twofold dilution series of the test compounds over the immobi-
lized Env surface. AH, GRFT, HHA, UDA, PRM-S, 2G12, Ab b12 and
mAb 2G12 were tested at following concentration ranges: 3.13–
50 nM; 1.56–12.5 nM; 3.13–25 nM; 3.13–25 nM; 781–3125 nM;
7.8–125 nM; 3.9–31.3 nM and 15.6–250 nM, respectively. The
samples were injected for 2 min at a ﬂow rate of 45 ll/min and
the dissociation between the Env molecule and the test molecules
was followed for 8 min. For all test molecules the CM5 surface was
regenerated with 1 injection (5 s at 100 ll/min) of 50 mM NaOH.
Only for 2G12 the regeneration pulse was performed with Gly-
cine–HCl pH1.5 during 20 s at 30 ll/min. At least three indepen-
dent experiments were carried out and gave essentially identical
results. Injections over blank CM5 surfaces and buffer blanks were
used for double referencing. The experimental data were ﬁt using
the 1:1 Langmuir binding model (Biacore T200 Evaluation software
1.0) to obtain the association rate constant ka (kon, on-rate), the dis-
sociation rate constant kd (koff, off-rate) and the afﬁnity constant KD
(ratio kd/ka).
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3.1. Expression of recombinant HIV-1 glycoproteins in mammalian
cells
The various Env proteins used in this study are derived from the
HIV-1 clade B strain JR-FL. The method to produce recombinant
Env monomers and trimers was previously described [18]. To gen-
erate the Env glycoproteins with an authentic human glycosylation
proﬁle the gp120 monomer and the gp140 trimer were expressed
in the human embryonic kidney (HEK) cell line 293T. This resulted
in monomeric JR-FL gp120 and trimeric JR-FL gp140 that both con-
tain a heterogeneous mixture of complex N-glycans and oligoman-
nose carbohydrates (designated as gp120WT and gp140WT,
respectively). In order to reduce the heterogeneity of Env glycosyl-
ation, the monomeric gp120 and trimeric gp140 glycoproteins
were also expressed in 293S GnTI/ cells that lack N-acetylglucos-
aminyltransferase I (GnTI) [30]. Carbohydrate analysis revealed
that Env proteins produced in GnTI/ cells exclusively contained
oligomannose sugars [29]. The absence of GnTI blocks the attach-
ment of GlcNAc to Man5GlNAc2 in the cis-Golgi compartment. This
means that complex carbohydrate sugars are not formed and the
most prevalent carbohydrate on the expressed glycoproteins are
oligomannose N-glycans containing ﬁve mannose residues. How-
ever, an important number of Man6-9GlcNAc2 entities are also pres-
ent on the Env glycoprotein because some mannose residues were
inefﬁciently trimmed [29]. The Env glycoproteins expressed in
293S GnTI/ cells will be referred to as gp120Man5-9 and
gp140Man5-9.
3.2. Characterisation of the oligomeric state of the Env proteins
Supernatants from the Env-transfected cell lines were analysed
under reducing conditions by SDS–PAGE and followed by Western
blot analysis. As depicted in Fig. 1 D7324-tagged gp120 and gp140
were secreted efﬁciently into the supernatants of these cell cul-
tures. Western blot analysis conﬁrmed that gp140 (Fig. 1, bands
in lanes 2 and 4) migrated with a higher apparent molecular
weight than gp120 (Fig. 1, bands in lane 1 and 3). When comparing
lane 4 with lane 2 and lane 3 with lane 1, it is evident that the Env-
Man5-9 glycoproteins migrated as more compact bands, which is
consistent with their decreased carbohydrate mass and decreased
heterogeneity.
To determine the oligomerization of gp120 and gp140, we per-
formed a BN-PAGE on the Env molecules produced either on HEK
293T cells or 293S GnTI/ cells. The gp120 Envs were secreted
predominantly as monomers and dimers, with some trimers beingFig. 1. The four Env constructs were visualized by SDS–PAGE analysis and Western blot
oligomannose-enriched gp120 (panel A, lane 1 and panel B, lane 3) and gp140 (panel A, la
and from 293T cells producing Env containing both complex and oligomannose N-glycan
respectively). The positions of the molecular mass marker proteins are indicated.present as well (Fig. 1B, bands in lane 1 and 3). No signiﬁcant
difference was observed between the oligomeric state of gp120
expressed by 293T or 293S cells; with the exception that 293S-pro-
duced gp120 migrated faster through the gel. Although gp120 can
spontaneously form dimers and trimers a strong shift in oligomer-
ization state was observed for both gp140 Env molecules that were
stabilized by an isoleucin zipper trimerization domain [29]. Their
migration patterns were consistent with the predominant presence
of trimers (Fig. 1B, bands in lane 2 and 4), but larger multimeric
complexes, probably representing aggregates of trimers, were also
visible.
3.3. Kinetic analysis of the interactions of CBAs and other gp120-
binding agents with the viral glycoproteins gp120 and gp140
We investigated the impact of the oligomeric state of the Env
glycoprotein (either monomeric gp120WT or trimeric gp140WT)
on the kinetic properties of their interaction with the CBAs. Actin-
ohivin (AH) and Grifﬁthsin (GRFT) (both lectins are endowed with
predominant a1,2-mannose oligomer speciﬁcity), Hippeastrum hy-
brid agglutinin (HHA) (a mana1,3/a1,6-mannose oligomer speciﬁc
plant lectin), Urtica dioica agglutinin (UDA) (a plant lectin with
GlcNAc-speciﬁcity), Pradimicin S (PRM-S) (an a1,2-mannose-spe-
ciﬁc non-peptidic antibiotic); the a1,2-mannose-directed gp120
Ab 2G12; Ab b12 that binds to the CD4 binding site of gp120 and
Ab 2F5 that interacts with a region on gp41 adjacent to the viral
membrane. When the kinetics were determined for the gp120-
binding agents against gp120WT and gp140WT, the CBAs (AH, GRFT,
HHA, UDA, PRM-S) and Ab 2G12 showed similar binding character-
istics independent of the oligomeric state of gp120 (Table 1, Fig. 3,
panels C and F). Both the association rates (represented by the ka
values) and the dissociation rates (represented by the kd values)
were very similar, resulting for each agent in similar KD binding
afﬁnity values for monomeric gp120WT and trimeric gp140WT.
There was a statistically non-signiﬁcant trend of a slightly higher
afﬁnity of the CBAs for monomeric gp120WT versus trimeric
gp140WT (with exception of AH) and this phenomenon was also
observed for sCD4 binding to gp120WT and gp140WT (P-value:
>0.05) (Table 1). This is in contrast to Ab b12 which binds to the
CD4 binding site of gp120 via protein/protein interactions and
not glycan/CBA interactions. Indeed, for Ab b12 the KD-value was
twofold lower against gp140WT trimer than gp120WT monomer,
and this was caused by a twofold slower dissociation rate of Ab
b12 from trimeric gp140WT (P-value: 0.013). In this respect, the ki-
netic properties observed for Ab b12 (lower KD for trimeric
gp140WT) were very similar to those of DC-SIGN. The dissociation
rate constant decreased even with a factor of 3 for DC-SIGNting (panel A) and by Blue Native Page (panel B). Supernatants were analysed from
ne 2 and panel B, lane 4) from 293S GnTI/ cells (i.e. gp120Man5-9 and gp140Man5-9)
s (i.e. gp120WT and gp140WT in panel A lanes 3 and 4 and in panel B lanes 1 and 2,
Table 1
Kinetic data of several CBAs and other gp120-binding agents for the interaction with monomeric gp120 and trimeric gp140.
HIV Env
binding
agent
Monomeric JR-FL gp120WT Trimeric JR-FL gp140WT Monomeric JR-FL gp120Man5-9 Trimeric JR-FL gp140Man5-9
KD (nM) ka (1/M s) kd (1/s) KD (nM) ka (1/M s) kd (1/s) KD (nM) ka (1/M s) kd (1/s) KD (nM) ka (1/M s) kd (1/s)
AH 13.3 ± 0.0 (3.42 ± 1.07)
E+06
(4.55 ± 1.12)
E02
9.5 ± 1.5 (3.80 ± 0.89)
E+06
(3.60 ± 0.57)
E02
6.0 ± 1.3 (1.11 ± 0.18)
E+07
(6.63 ± 1.05)
E02
5.7 ± 0.5 (8.17 ± 0.31)
E+06
(4.63 ± 0.25)
E02
GRFT 0.12 ± 0.02 (8.29 ± 0.95)
E+06
(9.80 ± 2.09)
E04
0.15 ± 0.01 (8.70 ± 1.95)
E+06
(3.60 ± 0.57)
E02
0.03 ± 0.01 (1.34 ± 0.19)
E+07
(3.88 ± 0.12)
E04
0.04 ± 0.02 (1.20 ± 0.40)
E+07
(4.42 ± 0.08)
E04
HHA 0.39 ± 0.06 (3.38 ± 0.49)
E+06
(1.13 ± 0.03)
E03
0.55 ± 0.03 (2.54 ± 0.13)
E+06
(1.40 ± 0.04)
E03
0.36 ± 0.07 (3.16 ± 0.20)
E+06
(1.14 ± 0.13)
E03
0.53 ± 0.07 (3.16 ± 0.78)
E+06
(1.68 ± 0.91)
E03
UDA 2.0 ± 0.4 (2.09 ± 0.49)
E+06
(4.38 ± 1.02)
E03
2.4 ± 0.4 (2.54 ± 0.09)
E+06
(6.03 ± 1.25)
E03
1.7 ± 0.0 (2.25 ± 0.28)
E+06
(3.92 ± 0.55)
E03
2.3 ± 0.1 (1.98 ± 0.36)
E+06
(4.46 ± 0.84)
E03
PRMS 662 ± 54 (7.66 ± 0.54)
E+04
(5.06 ± 0.39)
E02
1152 ± 124 (1.13 ± 0.01)
E+04
(1.31 ± 0.13)
E02
300 ± 27 (1.20 ± 0.20)
E+05
(3.57 ± 0.56)
E02
540 ± 98 (2.02 ± 0.27)
E+04
(1.07 ± 0.07)
E02
2G12 5.8 ± 54 (6.56 ± 0.74)
E+04
(3.81 ± 0.43)
E04
8.6 ± 0.5 (4.52 ± 0.01)
E+04
(3.90 ± 0.23)
E04
2.5 ± 0.1 (2.15 ± 0.37)
E+05
(5.31 ± 0.73)
E04
3.2 ± 0.2 (4.94 ± 0.98)
E+04
(2.85 ± 0.32)
E04
b12 3.0 ± 0.7 (1.34 ± 0.15)
E+06
(3.91 ± 0.48)
E03
1.6 ± 0.0 (1.17 ± 0.30)
E+06
(1.89 ± 0.47)
E03
3.9 ± 1.2 (8.00 ± 0.50)
E+05
(3.16 ± 0.56)
E03
1.9 ± 0.3 (7.97 ± 1.32)
E+05
(1.48 ± 0.80)
E03
2F5 No binding at 1 lM 4.2 ± 0.8 (8.48 ± 1.48)
E+04
(3.24 ± 0.25)
E04
Not determined Not determined
sCD4 90 ± 1.8 (1.41 ± 0.57)
E+04
(1.27 ± 0.26)
E03
152 ± 13 (1.03 ± 0.82)
E+04
(1.55 ± 0.12)
E03
89 ± 0.7 (1.20 ± 0.56)
E+04
(1.07 ± 0.06)
E03
178 ± 16 (1.81 ± 0.28)
E+04
(3.19 ± 0.19)
E03
DCSIGN 2.7 ± 0.6 (4.21 ± 0.64)
E+06
(1.15 ± 0.47)
E02
1.5 ± 0.0 (2.05 ± 0.81)
E+06
(3.17 ± 0.59)
E03
4.7 ± 0.6 (3.88 ± 0.66)
E+06
(1.80 ± 0.36)
E02
1.3 ± 0.1 (3.02 ± 0.48)
E+06
(3.83 ± 0.91)
E03
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was observed at 1 lM as expected, whereas the anti-gp120 Ab 2F5
resulted in a KD as low as 4.2 ± 0.8 nM against gp140WT (Fig. 2, pan-
els C and F).
3.4. Kinetic analysis of the interactions of CBAs and other gp120-
binding agents for the viral glycoproteins gp120 and gp41 that solely
consist of terminally mannosylated glycans
We also wanted to investigate the afﬁnity of the test com-
pounds against monomeric (gp120Man5-9) and trimericFig. 2. Surface plasmon resonance sensorgrams of sCD4, b12 and 2F5 binding to immobi
b12 (panels B, E, H and J) and 2F5 (panels C and F) with gp120WT, gp140WT, gp120Man5-9 a
surface of the immobilized Env proteins. The experimental data (colored curves) were ﬁ(gp140Man5-9) Env that consisted of a less heterogenic glycan shield
lacking complex-type glycans and solely containing mannosylated
glycans. The exclusive presence of Man5-9 oligomannose glycans
on gp120Man5-9 and gp140Man5-9 resulted in consistently lower KD
values for those CBAs that were predominantly a1,2-mannose-spe-
ciﬁc (i.e. CBAs AH, GRFT, PRM-S) and for the a1,2-mannose-direc-
ted Ab 2G12. The P-values for the higher afﬁnity interactions of the
a1,2-mannose-speciﬁc CBA agents gp120Man5-9 and gp140Man5-9
versus wild-type gp120WT and gp140WT were 0.010 (AH); 0.007
(GRFT), 0.026 (PRM-S) and 0.001 (Ab 2G12), respectively. No such
signiﬁcant change in KD values was detected for the a1,3/a1,lized Env proteins. Kinetic analysis of the interactions of sCD4 (panels A, D, G and I),
nd gp140Man5-9, respectively. Serial twofold analyte dilutions were injected over the
t using the 1:1 binding model (black lines) to determine the kinetic parameters.
Fig. 3. Kinetic analysis of the interactions of GRFT, HHA and 2G12 with the immobilized recombinant envelope glycoproteins using SPR technology. The kinetic proﬁle of
GRFT, HHA and 2G12 versus gp120WT, gp140WT, gp120Man5-9 and gp140Man5-9 is plotted in panels A, D, G and I; panels B, E, H and J and panel C, F, I and L, respectively. Serial
twofold analyte dilutions were injected over the surface of the immobilized Env proteins. The experimental data (colored curves) were ﬁt using the 1:1 binding model (black
lines) to determine the kinetic parameters.
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and DC-SIGN (P-values: >>0.05) (Table 1).
4. Discussion
A wide variety of gp120-binding agents have been subject of
SPR-based afﬁnity studies with monomeric HIV-1 gp120. But it re-
mains uncertain whether the gp120 monomer is a reliable substi-
tute for the native trimeric Env in such binding afﬁnity
determination studies. Therefore, we compared the drug interac-
tions of a variety of gp120-binding agents with monomeric JR-FL
gp120 (gp120WT) and trimeric JR-FL gp140 (gp140WT), but also
with the monomeric JR-FL gp120 (gp120Man5-9) and trimeric JR-
FL gp140 (gp140Man5-9) that bear mostly Man5GlcNAc2 sugars but
also signiﬁcant amounts of incompletely trimmed Man6-9GlcNAc2
sugars [29].
A non-signiﬁcant trend of a <twofold decrease in binding efﬁ-
ciency (higher KD) was observed against trimeric gp140WT versus
monomeric gp120WT and trimeric gp140Man5-9 versus monomeric
gp120Man5-9 for all agents, except for DC-SIGN and the Ab b12 that
showed a signiﬁcant stronger binding (lower KD) to trimeric gp140
than to monomeric gp120 (2- to 3.5-fold; P << 0.05) and for AH
that did not show a signiﬁcant difference in its KDs (Table 1). The
Ab b12 binds to gp120 through protein/protein interactions at an
epitope that overlaps with the CD4-binding site on gp120 [31]
and proved to have broad neutralizing activity [32]. DC-SIGN, a
C-type (Ca++-dependent) lectin of our innate immune system, has
known binding speciﬁcities for high-mannose glycans and for
fucose-containing glycans [33], and is able to recognize a wide
variety of (viral) pathogens through interaction of the carbohy-
drate-binding moiety of DC-SIGN and the sugar coat of the patho-
gens [34,35]. Nevertheless, BN-PAGE (Fig. 1B) implies that gp140
expressed in 293T cells and in 293S GnTI/ cell cultures efﬁcientlyformed trimers. Although it should be realized that the differences
in compound afﬁnities (KD) experimentally observed for mono-
meric gp120 and trimeric gp140 are relatively small, given the
exquisite afﬁnity against the viral Env for most of these agents
(KD often in the higher picomolar or lower nanomolar range), the
increased afﬁnity of Ab b12 and DC-SIGN for trimeric gp140 versus
monomeric gp120 was statistically signiﬁcant (P = 0.013 and 0.012,
respectively). The observed increased afﬁnity of Ab b12 and DC-
SIGN for trimeric gp140 versus monomeric gp120 was in both
cases mainly due to lower kd (off-rate) values. The underlying basis
for this phenomenon may be an avidity effect present upon their
binding to the trimeric gp140. In contrast, the binding afﬁnity of
2G12 that also recognizes high-mannose glycans, as DC-SIGN does,
and sCD4 that also binds to the CD4 binding site of gp120, as Ab
b12 does, is not increased for trimeric gp140 versus monomeric
gp120. The avidity effect could indeed not have played a role in
sCD4 binding to gp120. With regard to the 2G12 Ab, it has an unu-
sual structure that facilitates recognition of its carbohydrate epi-
tope on gp120 but its Fab arms are structured in such a manner
that a single antigen-binding region is created with two rigidly ar-
ranged antigen-binding sites separated by only 35 Å instead of
the usual 120–150 Å in IgG Abs (two 2G12 Fabs form one carbohy-
drate-binding site; six 2G12 Fabs bind to one gp120 trimer) [36].
Therefore, this unique structure of Ab 2G12 may compromise its
ability to afford an avidity effect as efﬁciently as normal IgGs can
do.
Several CBAs, that predominantly recognize a1,2-mannose olig-
omers (i.e. AH, GRFT, PRM-S and 2G12) showed a statistically sig-
niﬁcant increased afﬁnity (lower KD) for gp120Man5-9 and
gp140Man5-9 than for gp120WT and gp140WT, respectively. This is
in line with the higher density of high-mannose-type glycan struc-
tures present on gp120Man5-9 and gp140Man5-9 expressed in 293S
GnTI/ cell cultures [29]. Such glycan structures indeed
B. Hoorelbeke et al. / FEBS Letters 587 (2013) 860–866 865predominantly contain terminal a1,2-mannose residues and thus,
a1,2-mannose-speciﬁc CBAs would be expected to have a higher
binding efﬁcacy to such Env molecules. In fact, for 2G12 it has been
shown that it prefers Man9GlcNAc2 binding, in particular the
Mana1,2Man disaccharide terminal ends [37,38]. Although 2G12
was recently shown not to interact with a branched Man5 arms,
it did so with a linear Man4 arm as present in the Man9GlcNAc2 gly-
cans on HIV gp120 [39]. Although Man5 arms are certainly present
among the N-glycans of gp120 expressed GnTI/ cells, a marked
number of Man6-9GlcNAc2 entities are still present on the Env gly-
coprotein expressed by GnTI/ cells due to inefﬁciently trimmed
Man9GlcNAc2 [29]. Such Man6-9 GlcNAc2 glycans may then even
be better reached by 2G12 due to the shortening of the other N-
glycans to Man5GlcNAc2 explaining the somewhat lower KD of
2G12 for gp120 derived from GnTI/ cells. Thus, by SPR technol-
ogy, we could indeed pick-up such subtle differences in afﬁnity
for 2G12 and the other a1,2-mannose-speciﬁc CBAs. In contrast,
the a1,3/a1,6-mannose- and GlcNAc-speciﬁc CBAs (HHA, UDA),
the Abs b12 and 2F5, and sCD4 do not discriminate between both
types of Env molecules, as expected. Also DC-SIGN did not discrim-
inate between both gp120/gp140 sources, most likely due its broad
recognition of speciﬁc types of fucosylated glycans and subsets of
both oligomannose- and complex-type glycans [33].
Although SPR technology proved to be very useful to determine
and to compare afﬁnities (KD) of different analytes for a well-de-
ﬁned ligand (in this case HIV-1 gp120), such interactions do not
have any predictable value on the potential of the compounds to
neutralize the virus in cell culture or in HIV-infected individuals.
This mainly depends on the epitope the compounds may recognize.
In fact, non-neutralizing antibodies might bind equally well on
gp120 than neutralizing antibodies.
In conclusion, SPR analyses revealed that only minor differences
could be observed between monomeric and trimeric HIV-1 Env
with regard of the binding capacity and afﬁnity of a variety of CBAs,
mAbs directed to gp120, sCD4 and DC-SIGN. These ﬁndings reveal
that reliable kinetic data for gp120-CBA afﬁnities can be obtained
from SPR binding studies using monomeric gp120. The conclusions
of such studies should therefore have relevance for the trimeric
gp120 present in the virus particle and in the membrane of
virus-infected cells.Competing interests
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